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AAV2/8-humanFOXP3 gene therapy 
shows robust anti-atherosclerosis efficacy 
in LDLR-KO mice on high cholesterol diet
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Abstract 
Inflammation is a key etiologic component in atherogenesis. Previously we demonstrated that adeno‑associated 
virus (AAV) 2/8 gene delivery of Netrin1 inhibited atherosclerosis in the low density lipoprotein receptor knockout 
mice on high‑cholesterol diet (LDLR‑KO/HCD). One important finding from this study was that FOXP3 was strongly 
up‑regulated in these Netrin1‑treated animals, as FOXP3 is an anti‑inflammatory gene, being the master transcription 
factor of regulatory T cells. These results suggested that the FOXP3 gene might potentially be used, itself, as an agent 
to limit atherosclerosis. To test this hypothesis AAV2/8 (AAV)/hFOXP3 or AAV/Neo (control) gene therapy virus were 
tail vein injected into the LDLR‑KO/HCD animal model. It was found that hFOXP3 gene delivery was associated with 
significantly lower HCD‑induced atherogenesis, as measured by larger aortic lumen cross sectional area, thinner aortic 
wall thickness, and lower aortic systolic blood velocity compared with Neo gene‑HCD‑treated controls. Moreover 
these measurements taken from the hFOXP3/HCD‑treated animals very closely matched those measurements taken 
from the normal diet (ND) control animals. These data strongly suggest that AAV/hFOXP3 delivery gave a robust 
anti‑atherosclerosis therapeutic effect and further suggest that FOXP3 be examined more stringently as a therapeutic 
gene for clinical use.
© 2015 Cao et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Inflammation is now known to be a key regulatory pro-
cess that is common denominator among several risk 
factors for atherosclerosis, in addition to accompanying 
and associated altered arterial biology [1, 2]. Further-
more, it appears that both the innate and adaptive arms 
of the immune system may also be involved in this overall 
inflammatory trend which is implicated in atherosclero-
sis [3–7]. We have carried out various therapeutic adeno-
associated virus (AAV)-based gene therapy studies in an 
animal model of atherosclerosis (low-density lipopro-
tein receptor-knockout mouse on high cholesterol diet, 
LDLR-KO HCD), towards the specific goal of regulating 
the arterial immune cell infiltrate status with immuno-
suppressive cytokines and leukocyte chemo-attractant/
repellant chemokine genes, and thereby inhibiting ath-
erosclerosis [8–15].
We recently published a study that demonstrated 
that AAV/Netrin1 systemic gene delivery was able to 
inhibit atherosclerosis in LDLR-KO mice on HCD [13]. 
This was shown by high resolution ultrasound (HRUS) 
measurements of aortic lumen cross-sectional area, 
wall thickness, and systolic blood velocity. All of these 
measurements indicated that the Netrin1 gene deliv-
ery resulted in significantly lower atherosclerosis. How-
ever, upon analysis of the expression of various genes 
by Q-PCR we discovered that both Forkhead box P3’s 
(FOXP3) and CD25 expression were strongly up-regu-
lated in the AAV/Netrin1-treated animals [13]. Of course 
both FOXP3 and CD25 are hallmark markers of regula-
tory T cells (Treg). However, the exact mechanism by 
which FOXP3 and CD25 are up-regulated by Netrin1 in 
aortas challenged with HCD remains to be determined.
Of these two genes, FOXP3, in particular, the mas-
ter transcription factor of regulatory T cells (Treg), is 
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intriguing as a therapeutic gene as the Treg phenotype 
is tied to FOXP3 expression, and Treg affect both innate 
and adaptive immunity [3–7]. It is the induction of the 
FOXP3 gene which results in giving an immune suppres-
sive function to Treg precursor cells, and the removal of 
expression of this same gene in mature Treg cells results 
in loss of Treg lineage identity and a marked reduction 
in immunosuppressive properties [16–19]. Here we 
characterize the effect of AAV-based human (h)FOXP3 
gene delivery, by systemic tail vein injection, to inhibit 
atherosclerosis in the LDLR-KO/HCD animal model. In 
this study we use the human (h)FOXP3 transgene rather 
than the mouse (m)Foxp3 version as the hFOXP3 and 
mFOXP3 proteins are 86% homologous, and the use of 




All experimental procedures were performed in accord-
ance with protocols approved by the Institutional Ani-
mal Care and Usage Committee of the Central Arkansas 
Veterans Healthcare System, Research and Development, 
at Little Rock. The project was funded by a Veterans 
Administration Merit Review grant to PLH.
AAV vector construction and virus generation
We directly addressed the hypothesis that hFOXP3 gene 
delivery can inhibit atherosclerosis by using AAV2/8 
[AAV2 inverted terminal repeats (ITR) DNA combined 
with the AAV serotype 8 capsid] gene delivery. The 
human (h) FOXP3 cDNA was obtained from Open Bio-
systems and was ligated downstream from the cytomeg-
alovirus immediate early promoter (CMVpr) within the 
gutted AAV vector dl3-97 to generate AAV/hFOXP3. The 
AAV/Neo vector has been described previously [8, 10–
14]. AAV2/8 virus (AAV2 DNA in AAV8 virion) was pro-
duced using pDG8 helper and titered by dot blot analysis 
by standard methodologies [8, 10–14].
Animal treatments
LDLR-KO mice (B6;129S7-Ldlrtm1Her/J) were purchased 
from Jackson Laboratories (Bar Harbor, ME, USA). Three 
groups of male mice, composed of ten animals each at 
8 weeks old, were injected with AAV/Neo (positive control 
group), or AAV/hFOXP3 virus at a titer of 1 × 1010 e.g./
ml via tail vein with 200 μL virus per mouse, two booster 
injections were followed at an interval of 5–6 days. High 
cholesterol diet (HCD) of 4% cholesterol and 10% cocoa 
butter diet (Harlan Teklad, Madison, Wis, USA) was pro-
vided from the first day of injection and maintained for 
the entire study period. Another group of mice fed with 
a ND was used as a negative control group. The normal 
background mouse chow was Harlan catalog #7012, and 
the HCD was #7012, 4% cholesterol/10% cocoa butter, cus-
tom formulated by Harlan. All experimental procedures 
conform to protocols approved by the Institutional Animal 
Care and Usage Committee of the Central Arkansas Veter-
ans Health Care System at Little Rock.
Ultrasound imaging
Ultrasound imaging was carried out using a Vevo 770 
High-Resolution Imaging system (Visualsonics, Toronto, 
Canada) with a RMV 707B transducer having a center 
frequency of 30  MHz. Animal preparation was done as 
described earlier [20]. In brief, the mice were anesthe-
tized using 1.5% isoflurane (Isothesia, Abbott Labora-
tories, Chicago, USA) with oxygen and laid supine out 
on a thermostatically heated platform. Abdominal hair 
was removed with a shaver and a chemical hair remover 
(Church & Dwight Co, Inc., NJ, USA). A pre-warmed 
transducing gel (Medline Industries, Inc., Mundelein, 
USA) was spread over the skin as a coupling medium for 
more accurate measurements. Two general levels of the 
vessel were visualized: thoracic region—below the aortic 
arches to the diaphragm and then the renal region—the 
upper abdominal region to the iliac bifurcation. Image 
acquisition was started on B-mode, where, a long axis 
view was used to visualize the length of the aorta. Then 
the scan head probe was turned 90° for a short-axis view 
to visualize the cross-sectional area of the aorta. Indi-
vidual frames and cine loops (300 frames) were acquired 
at all levels of the aorta, and included both the long axis 
and short axis view and recorded at distances of 1  mm 
throughout the length of the aorta. Measurement of the 
flow velocity, orientation of the abdominal aorta by ultra-
sound, was accomplished by tilting the platform and the 
head of mouse down with the transducer probe towards 
the feet and tail of the mouse. This positioning resulted 
in the Doppler angle to be less than 60° for accurate 
measurements of blood flow velocity in the pulse-wave 
Doppler (PW) mode within abdominal aorta. Off-line 
measurements and data analysis was performed using the 
customized version of Vevo770 Analytical Software from 
both the longitudinal and transverse images. The com-
plete imaging for each mouse lasted for about 25–30 min.
Measurement of plasma cholesterol
Total plasma cholesterol of AAV/Neo and AAV/FOXP3 
mice were measured by VetScan VS2 (Abaxis, Union 
City, CA, USA) at the Veterans Animal Laboratory 
(VAMU).
Atherosclerotic lesion analysis by direct visualization
Whole dissected aortas were fixed in 10% buffered for-
malin, inspected under a dissecting microscope and any 
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small pieces of adventitial fat that remained attached 
were removed very carefully without disturbing the 
aorta itself and the internal lipid accumulations/plaque. 
Unstained small animal aortas are normally translucent 
but show lipid deposition as white areas [21, 22]. Aortas 
were then photographed under natural light using a 10 
megapixel digital camera (Nikon, Japan).
Observation of atherosclerosis by histology
Twenty weeks after first injection of virus and on HCD, 
mice were killed by CO2 exposure. Entire aortas, includ-
ing the aortic arches, thoracic and abdominal aor-
tas, were removed. The aorta was flushed with saline 
solution and fixed in 10% neutral buffered formalin 
(Sigma). After 24 h, the fixed tissue was used for paraf-
fin embedding and sectioning for histological analysis. 
Finally representative sections were hematoxylin and 
eosin-stained.
Statistics
Parameters were analyzed with statistics software SPSS 
16.0 by nonparametric ANOVA test. If differences were 
detected between means, Newman–Keuls test was used 
for multiple comparisons. Difference were considered as 
significant if P < 0.05.
Results
AAV vectors and animal treatments
We directly addressed the hypothesis that hFOXP3 gene 
delivery can inhibit atherosclerosis by using AAV2/8 
[AAV2 inverted terminal repeats (ITR) DNA combined 
with the AAV serotype 8 capsid] gene delivery. The 
AAV2/8-hFOXP3 was delivered by tail vein injection and 
the animals placed on HCD (4% cholesterol, 10% cocoa 
butter). Another animal group received AAV2/8-Neo 
virus delivered by tail vein injection and also placed on 
HCD, which served as positive controls. Lastly, a group 
of animals received only a ND and served as negative 
controls. The animals were then analyzed by high reso-
lution ultrasound and harvested at 20 weeks post-injec-
tion/post HCD initiation. Figure  1a shows the general 
structure of the AAV vectors used Figure  1b shows the 
overall structure of the experiments. We have previously 
demonstrated specific delivery and expression of mul-
tiple transgenes into the aorta by AAV2/8 (AAV2 DNA 
inside the AAV8 capsid), utilizing the CMVpr transcrip-
tional promoter, delivered by tail vein injection, to give 
expression levels 1.7-2.3% that of β-actin [10, 11]. Fig-
ure 2a shows that the blood cholesterol levels were high 
in both groups on HCD compared to the ND control. 
However, the AAV/hFOXP3-HCD and AAV/Neo-HCD 
treated animal were statistically different, with the AAV/
hFOXP3-HCD group having a slightly lower cholesterol 
level. In Figure 2b, animal weights were statistically simi-
lar in all groups.
Analysis of aortic structure
High resolution ultrasound (HRUS) was then used to 
analyze the aortas of at least eight animals per group. Fig-
ure  3 shows that the cross-sectional area of the lumens 
of the aortas was significantly larger (p  <  0.05) in the 
hFOXP3/HCD-treated animals than the Neo/HCD-
treated animals by HRUS. Moreover, the lumens of the 
aortas in the hFOXP3/HCD-treated animals versus the 
ND control animals (negative control) were statistically 
the same (not significant, NS). This evidence of robust 
efficacy was surprising to us as Netrin1 gene delivery, 
while showing efficacy, did not give this higher level of 
efficacy. Moreover, further HRUS analysis, as shown in 
Figure 4, indicated that aortic wall thickness was signifi-
cantly thinner (p  <  0.05) in the hFOXP3/HCD-treated 
animals than the Neo/HCD-treated, positive control 
animals. Additionally, the wall thickness of the aorta in 
the hFOXP3/HCD-treated animals and the ND control 
animals were statistically the same (not significant, NS). 
Thus, this additional evidence of robust efficacy fully 
supports the lumen area analysis. Figure  5 shows that 
the systolic blood velocity (systolic pulse wave velocity) 
in the aorta of the hFOXP3/HCD-treated animals was 
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Figure 1 Vector structure and experimental overview. a The struc‑
ture of the AAV virus vectors. b The overall structure of the study. The 
experimental details are provided in the “Methods” section.
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animals, again consistent with a lower level of athero-
sclerosis. In this additional measurement the wall thick-
ness of the aorta in the hFOXP3/HCD-treated animals 
and the ND control animals were statistically significant. 
However, it can also be easily observed that the systolic 
blood velocity of the hFOXP3/HCD-treated animals was 
much closer (lower) to the ND animals than to the Neo/
HCD-treated animals. The correlation between low sys-
tolic blood velocity with thinner aortic wall thickness and 
larger aortic lumens we observed here matches the cor-
relations we have seen in our other anti-atherosclerosis 
gene delivery studies in our studies of LDLR-KO mice 
on 4% cholesterol, 10% cocoa butter HCD [8, 10–14]. 
This again indicated that the hFOXP3 gene delivery did 
provide high level of efficacy against HCD-associated 
atherosclerosis.
Visual inspection of aortas
We further studied the effects of the transgene hFOXP3 




  900 
  800 
  700 
  600 
  500 
  400 
  300 











   






































   




















Figure 2 Animal characterization. a The levels of total cholesterol at 
week 20. b The animal weights at the end (week 20) of the experi‑
ment. The animals never received fasting conditions. p values of 
<0.05 refer to the student t test, are indicated by a “asterisk”, and also 
indicate statistical significance.
   












































Figure 3 Aortic lumen cross‑sectional area measurement. High reso‑
lution ultrasound (HRUS) was used to measure the cross‑sectional 
area for the aortas in 6–8 animals from each animal group by HRUS 
with representative captured images from the analysis shown just 
above. Note that the AAV/hFOX3P‑HCD animals had a larger cross 
sectional luminal area than the AAV/Neo‑HCD animals. Also note 
that the AAV/hFOX3P‑HCD and the ND groups were statistically the 
same. P values of <0.05 refer to the student t test, are indicated by a 
“asterisk”, and also indicate statistical significance.
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Figure 4 Aortic wall thickness measurement. HRUS was used to 
measure the wall thickness of the aorta. Shown is a quantification of 
the wall thickness of the aorta (thoracic region) of indicated groups 
with representative captured images from the analysis shown just 
above. Note that the AAV/hFOXP3‑HCD animals have a significantly 
thinner wall thickness than the AAV/Neo‑HCD animals. Also note 
that the AAV/hFOX3P‑HCD and the ND groups were statistically the 
same. p values of < 0.05 refer to the student t test, are indicated by a 
“asterisk”, and also indicate statistical significance.
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visual inspection. It has already been documented that 
unstained small animal aortas show lipid deposition 
as white areas [21, 22]. Figure  6a shows representative 
unstained aortas from the indicated animal groups. It is 
readily visible that the AAV/Neo-HCD-treated animals 
have much more numerous areas of white in both the 
aortic arch and in the descending aorta than either the 
ND or AAV/hFOXP3-HCD-treated animals. As the aor-
tic arch is particularly susceptible to atherosclerosis the 
aortic arches in these same aortas were further image 
enhanced using MS PowerPoint black-white 25% display 
as shown in Figure 6b. Again, consistent with the HRUS 
measurements, the AAV/hFOXP3-HCD-treated animal 
showed much less atherosclerosis than the AAV/Neo-
HCD-treated animal, and was very similar to the ND 
animal.
Histologic views of representative aortas
Finally, histologic sections were taken across the axis of 
the aortas to give representative cross sectional views. In 
Figure  7, representative hematoxylin and eosin-stained 
sections are shown, one each from each of three animals, 
from each of the three animal treatment groups. Note 
that the AAV/Neo-HCD group showed much higher 
levels of atherosclerotic plaque than either the ND or 
AAV/FOXP3-HCD group, consistent with the HRUS 
(Figures  3, 4, 5) and the direct visualization (Figure  6) 
analysis. The photomicrographs were further analyzed 
for smooth muscle layer thickness, but no statistical sig-
nificance was seen. However, within the AAV/Neo-HCD 
animal group an increase in smooth muscle layer thick-
ness of 61% (p < 0.05) was observed in regions associated 
with plaque compared to the opposing non-atheroscle-
rotic region of the same micrograph.
Discussion
Our earlier Netrin1 gene therapy study demonstrated 
that FOXP3 and CD25 were strongly overexpressed in 
aortas compared to controls [13], and that this over-








   































Figure 5 Systolic blood velocity measurement. High resolution 
ultrasound (HRUS) was used to quantify blood flow velocities in the 
luminal center of the aorta in 6–8 animals from each group with 
representative captured images from the analysis shown just above. 
Note that the AAV/hFOXP3‑HCD animals have a much lower blood 
velocity than the AAV/Neo‑HCD animals. Also note that the AAV/
hFOX3P‑HCD and the ND groups were very similar in peak systolic 
blood velocity. p values of < 0.05 refer to the student t test, are indi‑
cated by a “asterisk”, and also indicate statistical significance.
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Figure 6 Visual inspection of representative aortas. a Aortas from the 
indicated animals were buffered formalin‑fixed, cleaned and photo‑
graphed. Note that the AAV/Neo‑treated HCD aorta displays much 
higher amounts of lipid accumulation (white areas) than ether the 
AAV/hFOXP3‑HCD‑treated animals. b Shown is a PowerPoint black‑
white 25% enhancement of the aortic arch of the three aortas. Note 
that the AAV/Neo‑treated HCD aorta displays a much more extensive 
white area than ether the AAV/hFOXP3‑HCD‑treated or ND animals.
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atherosclerosis. From these results we developed the 
hypothesis that the Treg phenotype, specifically induced 
by AAV/FOXP3 gene delivery, would show an inhibi-
tion of atherogenesis in our LDLR-KO/HCD model. This 
study has demonstrated that our hypothesis was correct 
and that CMVpr-FOXP3-gene delivery by AAV2/8 vec-
tor results in a robust protection of aortas from devel-
oping atherosclerosis in the LDLR-KO/HCD model. 
The protection afforded by the FOXP3-treated animals 
on HCD was shown by the finding that multiple aortic 
parameters were not statistically different from the ND 
control group. These data suggest that the FOXP3 gene 
gives a high level of efficacy against HCD-induced ather-
osclerosis in the well-established LDLR/KO-HCD animal 
model. None of our other therapeutic gene therapy in 
LDLR-KO/HCD mouse studies has given multiple aortic 
parameters which were statistically the same as the ND 
control group [8, 10–14]. This includes our “gold stand-
ard” IL10 gene, which has been utilized by at least three 

















Figure 7 Histologic views of representative aortas. Aortas from each of three representative animals from the three indicated animal groups 
(indicated column) were buffered formalin‑fixed, paraffin‑embedded, sectioned and hematoxylin and eosin stained. Note that the higher level of 
atherosclerotic plaque in the AAV/Neo‑HCD‑treated group is readily apparent.
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Very likely the efficacious ability of FOXP3 lies in 
its role as the master transcription factor for the Treg 
development and phenotype. It is known that the loss 
of FOXP3 expression (or mutation FOXP3) results in 
increases in chronic autoimmunity [18]. The pheno-
type of FOXP3 knockouts gives the “scurfy” phenotype 
in mice and in humans generates the X-linked autoim-
munity–allergic dysregulation and immuno-dysreg-
ulation, X-linked syndromes [28, 29]. Tregs are also 
critical for lowering excess inflammation and giving 
tolerance to gut commensal microbes [30]. However, if 
present in extreme excess, Tregs may allow for dysplas-
tic and malignant cell growth and chronic infections 
through the governance of limited anti-tumor surveil-
lance or limited anti-pathogenic organism immune 
responses [30–32].
As we age it is clear that inflammation increases and 
becomes a major threat to health [33–35]. Thus, the use 
of Tregs, the promotion of the Treg phenotype, is one 
possible approach to broadly limit this increasing inflam-
mation, in the aged population. The use of AAV-based 
FOXP3 gene therapy, to promote the overall Treg phe-
notype, could be an effective therapeutic gene and agent 
against inflammation and diseases of the elderly. It is very 
important that the forced induction of the FOXP3 gene 
results in giving an immune suppressive function to Treg 
precursor cells, and that the removal of expression of this 
same gene in mature Treg cells results in loss of Treg lin-
eage identity and a marked reduction in immunosuppres-
sive properties [16, 19].
One possible mechanism for the AAV/hFOXP3-HCD 
animal group cholesterol levels being lower than the 
AAV/Neo-HCD group is the likelihood that Foxp3 is 
known to induce both transforming growth factor beta 
1 (TGFβ1) and interleukin 10 (IL10). Both of these are 
known to be associated with lower cholesterol levels and 
both of TGFβ1 and IL10 are known to inhibit the devel-
opment of atherosclerosis. Both inhibit macrophage traf-
ficking into the arterial wall intima and thereby inhibit 
macrophage accumulation and foam cell formation. 
Additionally it has been reported by Klingenberg et  al 
that Foxp3 expression is linked with lower cholesterol 
levels, as we see here [36]. Thus, in summary, our data 
on FOXP3 gene delivery, and, in addition, the general lit-
erature on FOXP3 suggests that it will likely be a robust 
therapeutic gene for the treatment of atherosclerosis
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